NCT02390817

Brief Summary

The study will be performed to evaluate motor response and awareness with using sugammadex during wakeup procedure in spine surgery. The investigator's goal is to investigate the effect of sugammadex on the state of consciousness and motor-somatosensorial evoked potentials.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Mar 2015

Typical duration for phase_4

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 12, 2015

Completed
17 days until next milestone

Study Start

First participant enrolled

March 1, 2015

Completed
17 days until next milestone

First Posted

Study publicly available on registry

March 18, 2015

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2017

Completed
Last Updated

March 5, 2018

Status Verified

October 1, 2016

Enrollment Period

2.4 years

First QC Date

February 12, 2015

Last Update Submit

March 2, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Time to consciousness

    time to obeying verbal commands after reversal of NMBAs

    30 min

Secondary Outcomes (2)

  • To assess Motor Evoked Potential values

    4 hours

  • To assess Somatosensorial Evoked Potential values

    4 hours

Study Arms (2)

Sugammadex

ACTIVE COMPARATOR

At the wakeup status Sugammadex 2 mg/kg single dose will perform.

Drug: Sugammadex

Neostigmine

PLACEBO COMPARATOR

At the wakeup status Neostigmine 0,04 mg/kg single dose will perform.

Drug: Neostigmine

Interventions

Administration of Sugammadex

Also known as: group I
Sugammadex

Administration of Neostigmine

Also known as: group II
Neostigmine

Eligibility Criteria

Age10 Years - 25 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • American society of anesthesiologists (ASA) physical status I-II patients
  • spine surgery
  • age

You may not qualify if:

  • ASA III and above
  • Patient refusal
  • neuromuscular disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Ebru Biricik

Adana, Sarıçam, Turkey (Türkiye)

Location

Çukurova University

Adana, Çukurova, Turkey (Türkiye)

Location

Related Publications (1)

  • Adamus M, Hrabalek L, Wanek T, Gabrhelik T, Zapletalova J. Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery. J Anesth. 2011 Oct;25(5):716-20. doi: 10.1007/s00540-011-1209-1. Epub 2011 Aug 13.

    PMID: 21842171BACKGROUND

Related Links

MeSH Terms

Conditions

Spinal Curvatures

Interventions

SugammadexNeostigmine

Condition Hierarchy (Ancestors)

Spinal DiseasesBone DiseasesMusculoskeletal Diseases

Intervention Hierarchy (Ancestors)

gamma-CyclodextrinsCyclodextrinsMacrocyclic CompoundsPolycyclic CompoundsDextrinsStarchGlucansPolysaccharidesCarbohydratesPhenylammonium CompoundsQuaternary Ammonium CompoundsAminesOrganic ChemicalsOnium Compounds

Study Officials

  • Ebru Biricik

    Medical Director

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
SCREENING
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Anesthesiologist

Study Record Dates

First Submitted

February 12, 2015

First Posted

March 18, 2015

Study Start

March 1, 2015

Primary Completion

August 1, 2017

Study Completion

August 1, 2017

Last Updated

March 5, 2018

Record last verified: 2016-10

Data Sharing

IPD Sharing
Will not share

Locations